Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation

Julie Marie Vose, James Olen Armitage, Philip Jay Bierman, Dennis D. Weisenburger, Mark Hutchins, Monroe D. Dowling, Daniel F. Moravec, Scot Sorensen, John Okerbloom, George Bascom, David Howe, P. Steven Johnson, Robert M. Landon, James Mailliard, Warren Pevnick, Mark Westberg, Anne Kessinger

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: Our objective was to evaluate the impact of high-dose therapy and autologous bone marrow transplantation as salvage treatment for recurrent non-Hodgkin's lymphoma in a defined group of patients from the Nebraska Lymphoma Study Group. Design: Patients treated initially by oncologists from the Nebraska Lymphoma Study Group between January 1983 and July 1987 who subsequently underwent autologous bone marrow transplantation for recurrent or refractory disease were evaluated for treatment outcome. Patients: Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma underwent high-dose therapy and autologous stem cell infusion in the time period reviewed. An initial doxorubicin (Adriamycin)-containing chemotherapy regimen had failed in all patients. The most favorable subgroup included 17 patients who were less then 60 years of age and had received no chemotherapy beyond their initial doxorubicin-containing regimen when referred for bone marrow transplantation. Results: The complete response rate to the highdose therapy was 52%, with an actuarial five-year disease-free survival of all patients treated of 40%. The overall survival at five years was 46%. Conclusions: High-dose chemo-radiotherapy, followed by infusion of autologous hematopoietic stem cells, can effectively function as salvage therapy in a significant number of patients in whom primary chemotherapy regimens for non-Hodgkin's lymphoma fail. This treatment approach appears to offer superior results when compared with the reported outcome for patients treated with salvage chemotherapy administered at conventional doses.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalThe American journal of medicine
Volume87
Issue number3
DOIs
StatePublished - Sep 1989

Fingerprint

Salvage Therapy
Autologous Transplantation
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Doxorubicin
Drug Therapy
Lymphoma
Therapeutics
Hematopoietic Stem Cells
Disease-Free Survival
Radiotherapy
Stem Cells
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. / Vose, Julie Marie; Armitage, James Olen; Bierman, Philip Jay; Weisenburger, Dennis D.; Hutchins, Mark; Dowling, Monroe D.; Moravec, Daniel F.; Sorensen, Scot; Okerbloom, John; Bascom, George; Howe, David; Johnson, P. Steven; Landon, Robert M.; Mailliard, James; Pevnick, Warren; Westberg, Mark; Kessinger, Anne.

In: The American journal of medicine, Vol. 87, No. 3, 09.1989, p. 285-288.

Research output: Contribution to journalArticle

Vose, JM, Armitage, JO, Bierman, PJ, Weisenburger, DD, Hutchins, M, Dowling, MD, Moravec, DF, Sorensen, S, Okerbloom, J, Bascom, G, Howe, D, Johnson, PS, Landon, RM, Mailliard, J, Pevnick, W, Westberg, M & Kessinger, A 1989, 'Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation', The American journal of medicine, vol. 87, no. 3, pp. 285-288. https://doi.org/10.1016/S0002-9343(89)80152-4
Vose, Julie Marie ; Armitage, James Olen ; Bierman, Philip Jay ; Weisenburger, Dennis D. ; Hutchins, Mark ; Dowling, Monroe D. ; Moravec, Daniel F. ; Sorensen, Scot ; Okerbloom, John ; Bascom, George ; Howe, David ; Johnson, P. Steven ; Landon, Robert M. ; Mailliard, James ; Pevnick, Warren ; Westberg, Mark ; Kessinger, Anne. / Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. In: The American journal of medicine. 1989 ; Vol. 87, No. 3. pp. 285-288.
@article{513f9caf055947d0ad6598ff2502b2ce,
title = "Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation",
abstract = "Purpose: Our objective was to evaluate the impact of high-dose therapy and autologous bone marrow transplantation as salvage treatment for recurrent non-Hodgkin's lymphoma in a defined group of patients from the Nebraska Lymphoma Study Group. Design: Patients treated initially by oncologists from the Nebraska Lymphoma Study Group between January 1983 and July 1987 who subsequently underwent autologous bone marrow transplantation for recurrent or refractory disease were evaluated for treatment outcome. Patients: Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma underwent high-dose therapy and autologous stem cell infusion in the time period reviewed. An initial doxorubicin (Adriamycin)-containing chemotherapy regimen had failed in all patients. The most favorable subgroup included 17 patients who were less then 60 years of age and had received no chemotherapy beyond their initial doxorubicin-containing regimen when referred for bone marrow transplantation. Results: The complete response rate to the highdose therapy was 52{\%}, with an actuarial five-year disease-free survival of all patients treated of 40{\%}. The overall survival at five years was 46{\%}. Conclusions: High-dose chemo-radiotherapy, followed by infusion of autologous hematopoietic stem cells, can effectively function as salvage therapy in a significant number of patients in whom primary chemotherapy regimens for non-Hodgkin's lymphoma fail. This treatment approach appears to offer superior results when compared with the reported outcome for patients treated with salvage chemotherapy administered at conventional doses.",
author = "Vose, {Julie Marie} and Armitage, {James Olen} and Bierman, {Philip Jay} and Weisenburger, {Dennis D.} and Mark Hutchins and Dowling, {Monroe D.} and Moravec, {Daniel F.} and Scot Sorensen and John Okerbloom and George Bascom and David Howe and Johnson, {P. Steven} and Landon, {Robert M.} and James Mailliard and Warren Pevnick and Mark Westberg and Anne Kessinger",
year = "1989",
month = "9",
doi = "10.1016/S0002-9343(89)80152-4",
language = "English (US)",
volume = "87",
pages = "285--288",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Bierman, Philip Jay

AU - Weisenburger, Dennis D.

AU - Hutchins, Mark

AU - Dowling, Monroe D.

AU - Moravec, Daniel F.

AU - Sorensen, Scot

AU - Okerbloom, John

AU - Bascom, George

AU - Howe, David

AU - Johnson, P. Steven

AU - Landon, Robert M.

AU - Mailliard, James

AU - Pevnick, Warren

AU - Westberg, Mark

AU - Kessinger, Anne

PY - 1989/9

Y1 - 1989/9

N2 - Purpose: Our objective was to evaluate the impact of high-dose therapy and autologous bone marrow transplantation as salvage treatment for recurrent non-Hodgkin's lymphoma in a defined group of patients from the Nebraska Lymphoma Study Group. Design: Patients treated initially by oncologists from the Nebraska Lymphoma Study Group between January 1983 and July 1987 who subsequently underwent autologous bone marrow transplantation for recurrent or refractory disease were evaluated for treatment outcome. Patients: Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma underwent high-dose therapy and autologous stem cell infusion in the time period reviewed. An initial doxorubicin (Adriamycin)-containing chemotherapy regimen had failed in all patients. The most favorable subgroup included 17 patients who were less then 60 years of age and had received no chemotherapy beyond their initial doxorubicin-containing regimen when referred for bone marrow transplantation. Results: The complete response rate to the highdose therapy was 52%, with an actuarial five-year disease-free survival of all patients treated of 40%. The overall survival at five years was 46%. Conclusions: High-dose chemo-radiotherapy, followed by infusion of autologous hematopoietic stem cells, can effectively function as salvage therapy in a significant number of patients in whom primary chemotherapy regimens for non-Hodgkin's lymphoma fail. This treatment approach appears to offer superior results when compared with the reported outcome for patients treated with salvage chemotherapy administered at conventional doses.

AB - Purpose: Our objective was to evaluate the impact of high-dose therapy and autologous bone marrow transplantation as salvage treatment for recurrent non-Hodgkin's lymphoma in a defined group of patients from the Nebraska Lymphoma Study Group. Design: Patients treated initially by oncologists from the Nebraska Lymphoma Study Group between January 1983 and July 1987 who subsequently underwent autologous bone marrow transplantation for recurrent or refractory disease were evaluated for treatment outcome. Patients: Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma underwent high-dose therapy and autologous stem cell infusion in the time period reviewed. An initial doxorubicin (Adriamycin)-containing chemotherapy regimen had failed in all patients. The most favorable subgroup included 17 patients who were less then 60 years of age and had received no chemotherapy beyond their initial doxorubicin-containing regimen when referred for bone marrow transplantation. Results: The complete response rate to the highdose therapy was 52%, with an actuarial five-year disease-free survival of all patients treated of 40%. The overall survival at five years was 46%. Conclusions: High-dose chemo-radiotherapy, followed by infusion of autologous hematopoietic stem cells, can effectively function as salvage therapy in a significant number of patients in whom primary chemotherapy regimens for non-Hodgkin's lymphoma fail. This treatment approach appears to offer superior results when compared with the reported outcome for patients treated with salvage chemotherapy administered at conventional doses.

UR - http://www.scopus.com/inward/record.url?scp=0024465452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024465452&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(89)80152-4

DO - 10.1016/S0002-9343(89)80152-4

M3 - Article

C2 - 2672808

AN - SCOPUS:0024465452

VL - 87

SP - 285

EP - 288

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -